Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Terconazole

FDA-approved product (cream, vaginal), marketed as Terazol 3, Terazol 7, Terconazole.

Registered studies
10
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Terconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Terconazole. Its therapeutic class is shown instead.

WHO therapeutic group
Triazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC G01AG02; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Terconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Terconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Boric Acid vs. Terconazole in Treatment of RVVC

    NCT04208555 · start 2020-01-15

    Registered record
    Registry ID
    NCT04208555
    Conditions
    Vulvovaginal Candidiasis
    Interventions
    Boric Acid Vaginal Suppository; Terconazole Vaginal Suppository
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-01-15
    Completion
    2021-05-31
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvovaginal Candidiasis
    InterventionBoric Acid Vaginal Suppository; Terconazole Vaginal Suppository
    PhaseNot applicable
    Registry statusUnknown

  • Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis

    NCT03473418 · start 2018-04-01

    Registered record
    Registry ID
    NCT03473418
    Conditions
    Vaginal Candidiasis
    Interventions
    Ketoconazole; Terconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-04-01
    Completion
    2019-04-01
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaginal Candidiasis
    InterventionKetoconazole; Terconazole
    PhasePhase 3
    Registry statusUnknown

  • Multi-Center Study of New Medications to Treat Vaginal Infections

    NCT02308007 · start 2015-06

    Registered record
    Registry ID
    NCT02308007
    Conditions
    Vaginal Infection
    Interventions
    Terconazole; Metronidazole; Terconazole/metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06
    Completion
    2018-06
    Enrolment
    475

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaginal Infection
    InterventionTerconazole; Metronidazole; Terconazole/metronidazole
    PhasePhase 3
    Registry statusCompleted

  • Multi-Center Study of New Medications to Treat Vaginal Infections

    NCT02308033 · start 2015-06

    Registered record
    Registry ID
    NCT02308033
    Conditions
    Vaginal Infection
    Interventions
    Metronidazole; Gel vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06
    Completion
    2017-06
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaginal Infection
    InterventionMetronidazole; Gel vehicle
    PhasePhase 3
    Registry statusCompleted

  • Multi-Center Study of New Medications to Treat Vaginal Infections

    NCT02308046 · start 2015-06

    Registered record
    Registry ID
    NCT02308046
    Conditions
    Vaginal Infection
    Interventions
    Terconazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06
    Completion
    2017-06
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaginal Infection
    InterventionTerconazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

    NCT01813162 · start 2013-12

    Registered record
    Registry ID
    NCT01813162
    Conditions
    HIV Prevention
    Interventions
    Tenofovir 1% gel; Vaginal product
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-12
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention
    InterventionTenofovir 1% gel; Vaginal product
    PhasePhase 1
    Registry statusCompleted

  • Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

    NCT02180100 · start 2013-08

    Registered record
    Registry ID
    NCT02180100
    Conditions
    Vulvovaginal Candidiasis
    Interventions
    Terconazole Vaginal Suppository; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-08
    Completion
    2014-06
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvovaginal Candidiasis
    InterventionTerconazole Vaginal Suppository; Fluconazole
    PhasePhase 4
    Registry statusCompleted

  • A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

    NCT01867164 · start 2007-12

    Registered record
    Registry ID
    NCT01867164
    Conditions
    Vaginitis; Infectious Vaginosis
    Interventions
    Gynoclin V; Vagitrol V
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-12
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaginitis; Infectious Vaginosis
    InterventionGynoclin V; Vagitrol V
    PhasePhase 3
    Registry statusCompleted

  • Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network

    NCT00503542 · start 2007-02

    Registered record
    Registry ID
    NCT00503542
    Conditions
    Vaginitis
    Interventions
    Terazol or oral fluconazole for candidal vaginitis; Metronidazole or Clindamycin for Bacterial Vaginosis; Flagyl for definitively diagnosed vaginal trichomoniasis; Empiric Management
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2007-02
    Completion
    2008-02
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaginitis
    InterventionTerazol or oral fluconazole for candidal vaginitis; Metronidazole or Clindamycin for Bacterial Vaginosis; Flagyl for definitively diagnosed vaginal trichomoniasis; Empiric Management
    PhaseEarly phase 1
    Registry statusCompleted

  • Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis

    NCT00803738 · start 2002-12

    Registered record
    Registry ID
    NCT00803738
    Conditions
    Vulvovaginal Candidiasis
    Interventions
    Terconazole Vaginal Suppository; Terazol Vaginal Suppository
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-12
    Enrolment
    572

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvovaginal Candidiasis
    InterventionTerconazole Vaginal Suppository; Terazol Vaginal Suppository
    PhaseNot applicable
    Registry statusCompleted